Vernakalant

CHEMBL2111112 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

349.5 g/mol

LogP

2.9

Phase

4

Vernakalant is an atrial-selective antiarrhythmic agent that blocks cardiac potassium channels (IKur, IKAch) and sodium channels preferentially in atrial tissue due to their higher firing rates, with minimal ventricular electrophysiological effects. It is used for the rapid pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm. Its atrial selectivity reduces the risk of ventricular proarrhythmia compared to non-selective antiarrhythmic agents.

Moleküler Ağırlık

349,5000 g/mol

LogP

2,90

TPSA

51,20 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC

InChI

InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1

Molecular Formula

C20H31NO4

HBD / HBA

1 / 5

Döndürülebilir Bağlar

7

Ağır Atomlar

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Vernakalant is an atrial-selective antiarrhythmic agent that blocks cardiac potassium channels (IKur, IKAch) and sodium channels preferentially in atrial tissue due to their higher firing rates, with minimal ventricular electrophysiological effects. It is used for the rapid pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm. Its atrial selectivity reduces the risk of ventricular proarrhythmia compared to non-selective antiarrhythmic agents.

Yes, Vernakalant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111112. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9930049. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Vernakalant PillFYI'da

Yapı

Hızlı Veriler

Formül: C20H31NO4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.